IRF1 and rheumatoid arthritis: However, we found in this study that IRF1 appears to be clinically efficacious for the inhibition of chronic and delayed inflammation of RA, and that target therapy using IRF1 may entail fewer immunogenic systemic immunodeficiency problems than do therapies using TNF antibodies.